AXGN
AxoGen, Inc.
AXGN lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve.
AXGN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Stable |
AXGN's revenue and cash flow are currently healthy, and its balance sheet is stable, but its profitability is under pressure.
AXGN PE Valuation
AXGN has no meaningful PE right now: it lost money over the past year.
AXGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for AXGN, with profitability improving.
AXGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.65 | — |
| Q3 2026 | -$0.65 | -$0.59 |
| Q2 2026 | -$0.68 | -$0.57 |
| Q1 2026 | -$0.64 | -$0.48 |
| Q4 2025 | -$0.34 | -$0.11 |
| Q3 2025 | -$0.06 | +$0.25 |
| Q2 2025 | -$0.11 | +$0.26 |
| Q1 2025 | -$0.16 | +$0.33 |
| Q4 2024 | -$0.23 | +$0.28 |
AXGN lost $0.65 per share over the past year, a bigger loss than the year before.
AXGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $75.8M | +26% |
| Q2 2026 | $69.7M | +23% |
| Q1 2026 | $61.5M | +27% |
| Q4 2025 | $59.9M | +21% |
| Q3 2025 | $60.1M | +24% |
| Q2 2025 | $56.7M | +18% |
| Q1 2025 | $48.6M | +17% |
| Q4 2024 | $49.4M | +15% |
AXGN's revenue has grown year over year for 18 quarters in a row: $76M last quarter, up 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.3% | -1.9 points |
| Q2 2026 | -3.1% | -6 points |
| Q1 2026 | -4.6% | -1.2 points |
| Q4 2025 | -16% | -20 points |
| Q3 2025 | 3.2% | +3.8 points |
| Q2 2025 | 3% | +3.8 points |
| Q1 2025 | -3.4% | +7.6 points |
| Q4 2024 | 4.1% | +12 points |
AXGN's operating margin was 1.3% last quarter, down 1.9 points from the same quarter a year ago.
AXGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $15.1M | +789% |
| Q2 2026 | $6.3M | -9.7% |
| Q1 2026 | -$1.2M | +$12.2M |
| Q4 2025 | $1.8M | -78% |
| Q3 2025 | $1.7M | -48% |
| Q2 2025 | $7M | +115% |
| Q1 2025 | -$13.4M | -$245K |
| Q4 2024 | $8.1M | +$9.7M |
AXGN has burned cash in most quarters: $22M over the past year, about seven times what it generated the year before.
AXGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +15% | +8.2M shares |
| 1 year | +25% | +12.4M shares |
| 3 years | +43% | +18.5M shares |
| 5 years | +48% | +20.1M shares |
| Available history | +55% | +21.8M shares |
AXGN has 62M diluted shares, up 25% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | $639,000 |
AXGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 2.3x | Moderate |
| Q2 2025 | 3.3x | Elevated |
| Q1 2025 | 4.7x | High |
| Q4 2024 | 6.3x | High |
AXGN's net debt is about 2.3 years of its operating earnings (EBITDA).
AXGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.0 | Neutral |
| Stochastic | 83.0 | Overbought |
AXGN's weekly RSI is 66 (neutral) and its Stochastic is 83 (overbought).
AXGN PE vs Healthcare Sector
AXGN has no meaningful PE right now: it lost money over the past year.
AXGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $43.1 | 29% above |
| 20 week MA | $44.2 | 25% above |
| 50 week MA | $39.2 | 41% above |
| 100 week MA | $27.8 | 100% above |
| 200 week MA | $18.3 | 203% above |
AXGN is in an uptrend: it's above all five of its weekly moving averages, and 203% above its 200-week average.
AXGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.6 | $17.7 | -4.8% |
| 2021 | $17.7 | $9.82 | -45% |
| 2022 | $9.82 | $9.94 | +1.2% |
| 2023 | $9.94 | $6.83 | -31% |
| 2024 | $6.83 | $16.7 | +144% |
| 2025 | $16.7 | $32.8 | +97% |
| 2026 YTD | $32.8 | $55.4 | +69% |
AXGN's yearly returns have swung widely, from +144% in 2024 to −45% in 2021. It's up 69% so far in 2026.